Using engineered T-BsAb, we tested and confirmed the therapeutic value of using T cells to target Il1rl1, to eliminate LSC and the inhibitory tumor microenvironment, using mouse specific antibodies against mouse leukemias in immunocompetent mice, and human specific antibodies against human cell line xenografts and human PDXs. This evidence concerns the gene IL1RL1 and neoplasm.